Adaptive Pharmacotherapy for Smoking Cessation

Summary

The purpose of this study is to assess an "adaptive" approach to smoking cessation pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the Nicotine Patch. The investigators hypothesize that participants allocated to adaptive therapy will show significantly higher biochemically confirmed 30-day continuous abstinence at 12 weeks post-Target Quit Day (TQD).

Timeline

Start

2017-06-06

Primary completion

2020-07-30

Completion

2021-05-12

Outcome

Met primary endpoint

paper 23 of 95 participants (24%) in the adaptive treatment group and 8 of 93 participants (9%) in the standard treatment PMID 37682573 ↗

paper (odds ratio [OR], 3.38; 95% CI, 1.43-7.99; P = .004) PMID 37682573 ↗

paper This randomized clinical trial found that adaptive pharmacotherapy was efficacious for smoking cessation treatment in a practice setting. PMID 37682573 ↗

Publications

• Davis JM, Masclans L, Rose JE. Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial. JAMA Netw Open. 2023 Sep 5;6(9):e2332214. doi: 10.1001/jamanetworkopen.2023.32214.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	—	—
Subject	Nicotine	Unknown	—	—
Subject	Varenicline	Small molecule	—	—

Indications